Vaccination with B16 melanoma cells expressing a secreted form of interleukin-1β induces tumor growth inhibition and an enhanced immunity against the wild-type B16 tumor

Cancer Gene Therapy

Volumn 7, Issue 10, 2000, Pages 1365-1374

  Björkdahl, Olle ^a   Dohlsten, Mikael ^a,b   Sjögren, Hans Olov ^a  

^a LUND UNIVERSITY   (Sweden)

^b ASTRAZENECA R AND D   (Sweden)

Author keywords

B16; Gene therapy; Immunity; Interleukin 1 ; Signal sequence

Indexed keywords

GAMMA INTERFERON; INTERLEUKIN 1BETA; INTERLEUKIN 2;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CONTROLLED STUDY; FEMALE; GENE TRANSFER; IMMUNE RESPONSE; IMMUNITY; MELANOMA B16; MELANOMA CELL; MOUSE; NATURAL KILLER CELL; NONHUMAN; PRIORITY JOURNAL; SIGNAL TRANSDUCTION; SPLEEN CELL; TUMOR GROWTH; VACCINATION;

ANIMALIA;

EID: 0033759457     PISSN: 09291903     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.cgt.0242     Document Type: Article

References (49)

1. Local cytokine availability elicits tumor rejection and systemic immunity through granulocyte-T-lymphocyte cross-talk
2. Current progress in the gene therapy of cancer
3. Gene transfer as cancer therapy
4. Molecular approaches to cancer immunotherapy
5. A new era for cancer immunotherapy based on the genes that encode cancer antigens
6. Ex-vivo gene therapy using cytokine-transduced tumor vaccines: Molecular and clinical pharmacology
7. Gene transfer of a hybrid interleukin-1β gene to B16 mouse melanoma recruits leukocyte subsets and reduces tumour growth in vivo
8. Biologic basis for interleukin-1 in disease
9. Antitumor and immunotherapeutic effects of activated invasive T lymphoma cells that display short-term interleukin 1α expression
10. Interleukin-1 and interleukin-1 antagonism
11. Interleukin-1 receptor antagonist
12. The type II 'decoy' receptor: A novel regulatory pathway for interleukin 1
13. Interleukin 1 is processed and released during apoptosis
14. Release of IL-1 from mononuclear phagocytes
15. The secretory route of the leaderless protein interleukin 1β involves exocytosis of endolysosome-related vesicles
16. Fusion of a signal sequence to the interleukin-1β gene directs the protein from cytoplasmic accumulation to extracellular release
17. Selection of successive tumour lines for metastasis
18. A safe packaging line for gene transfer: Separating viral genes on two different plasmids
19. Monoclonal antibodies to human recombinant interleukin-1 (IL-1)β: Quantitation of IL-1β and inhibition of biological activity
20. Human tumor antigens recognized by T lymphocytes
21. Tumor immunotherapy by vaccination with cytokine gene-transfected cells
22. + T-cells
23. The differential effects of human leukocyte pyrogen/lymphocyte-activating factor, T cell growth factor, and interferon on human natural killer activity
24. Systemic IL-1 and adjuvant treatment of an experimental tumor: Immune status during primary tumor challenge
25. Role of interleukin 1 in promoting human monocyte-mediated tumor cytotoxicity
26. Vaccination with irradiated tumor cells engineered to secrete murine granulocyte-macrophage colony-stimulating factor stimulates potent, specific, and long-lasting anti-tumor immunity
27. Retroviral vector-mediated γ-interferon gene transfer into tumor cells generates potent and longlasting antitumor immunity
28. Interleukin 2 gene transfer into tumor cells abrogates tumorigenicity and induces protective immunity
29. Synergism between IFN-γ and IL-1α/β in growth inhibition of an allografted tumor
30. Involvement of immune responses in the eradication of IL-1α genetransduced tumour cells: Mechanisms of tumour rejection and immunotherapeutical implications
31. The biological properties of interleukin-1
32. Immunologic self-tolerance maintained by activated T cells expressing IL-2 receptor α-chains (CD25): Breakdown of a single mechanism of self-tolerance causes various autoimmune diseases
33. Type 1 versus type 2 cytokine release by Vβ T cell subpopulations determines in vivo antitumor reactivity: IL-10 mediates a suppressive role
34. Gene-modified tumor vaccine with therapeutic potential shifts tumor-specific T cell response from a type 2 to a type 1 cytokine profile
35. Therapy of murine tumors with tumor peptide-pulsed dendritic cells: Dependence on T cells, B7 costimulation, and T helper cell 1-associated cytokines
36. Early-appearing tumour-infiltrating natural killer cells play a crucial role in the generation of anti-tumour T lymphocytes
37. T cell-mediated, IFN-γ-facilitated rejection of murine B16 melanomas
38. In vivo priming of two distinct antitumor effector populations: The role of MHC class I expression
39. MHC class I expression on tumor targets inhibits natural killer cell-mediated cytotoxicity without interfering with target recognition
40. A phase I trial of recombinant human interleukin-1β alone and in combination with myelosuppressive doses of 5-fluorouracil in patients with gastrointestinal cancer
41. Systemic IL-1 and adjuvant treatment of an experimental tumor: Immune status following tumor rechallenge
42. Anti-tumour effects of interleukin 1β: In vivo induction of immunity to B16 melanoma, a non-immunogenic tumour
43. The toxic and hematologic effects of interleukin-1α administered in a phase I trial to patients with advanced malignancies
44. Phase I trial of escalating doses of interleukin-1β in combination with a fixed dose of interleukin-2
45. Involvement of the very late antigen 4 integrin on melanoma in interleukin 1-augmented experimental metastases
46. Interleukin 1-induced augmentation of experimental metastases from a human melanoma in nude mice
47. Interleukin 1 (IL-1)-dependent melanoma hepatic metastasis in vivo: Increased endothelial adherence by IL-1-induced mannose receptors and growth factor production in vitro
48. In vivo gene therapy of a murine pancreas tumor with recombinant vaccinia virus encoding human interleukin-1β
49. Immunotherapy of bladder cancer with cytokine gene-modified tumor vaccines